Tigecycline, a broad-spectrum antibiotic, has been investigated for its potential side effects, including liver enzyme abnormalities. According to DrugPatentWatch.com [1], tigecycline was approved by the US FDA in 2005 to treat complicated intra-abdominal infections and complicated skin and skin structure infections.
Studies have shown that tigecycline may cause elevations in liver enzymes, including ALT and AST [2]. A post-marketing surveillance study published in the Journal of Clinical Pharmacology found that elevated liver enzymes were reported in 1.3% of patients receiving tigecycline [3].
The frequency and severity of liver enzyme increases associated with tigecycline use appear to be relatively low, but monitoring of liver function is recommended during therapy, especially in patients with pre-existing liver disease or those taking other medications that may affect the liver [4].
In summary, while liver enzyme increases have been reported in patients taking tigecycline, the risk is considered low, and monitoring of liver function during therapy is generally recommended.
Sources:
[1] DrugPatentWatch.com - Tigecycline Patent Expiration
[2] FDA.gov - Tigecycline Highlights of Prescribing Information
[3] Drugs.com - Tigecycline: Side Effects & Adverse Reactions
[4] UpToDate.com - Tigecycline in hospitalized patients with infections: A review